CN102008678A - Chinese medicinal preparation for treating fatty liver - Google Patents
Chinese medicinal preparation for treating fatty liver Download PDFInfo
- Publication number
- CN102008678A CN102008678A CN 201010587217 CN201010587217A CN102008678A CN 102008678 A CN102008678 A CN 102008678A CN 201010587217 CN201010587217 CN 201010587217 CN 201010587217 A CN201010587217 A CN 201010587217A CN 102008678 A CN102008678 A CN 102008678A
- Authority
- CN
- China
- Prior art keywords
- grams
- fatty liver
- chinese medicinal
- liver
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal preparation for treating fatty liver for meeting the safe and efficient requirements of fatty liver treatment. The Chinese medicinal preparation is prepared from the following raw Chinese medicinal materials by weight: 10 to 30 grams of many-flower solomonseal rhizome, 10 to 15 grams of medlar, 12 to 30 grams of Chinese white olive, 6 to 15 grams of figwort, 3 to 6 grams of villous amomum fruit, 12 to 20 grams of pueraria flower, 3 to 6 grams of cardamom, 10 to 15 grams of oriental waterplantain rhizome, 3 to 12 grams of large-headed atractylodes rhizome, 10 to 30 grams of tuckahoe and 10 to 15 grams of agaric. By observing Chinese medicinal symptoms, physical signs, syndrome integrals and liver B ultrasonic image change conditions of 78 cases of a treatment group before and after treatment and evaluating the clinical effect, results show that the total effective rate of the treatment group is obviously superior to that of a control group, and the difference has statistical significance (P is less than 0.05). The Chinese medicinal preparation has good clinical effect of treating the fatty liver.
Description
Technical field
The invention belongs to pharmaceutical product, particularly have the fatty liver treatment Chinese medicine of hepatoprotective effect.
Background technology
Fatty liver is meant because the pathological changes of the interior fatty overheap of the hepatocyte that a variety of causes causes.The positive serious threat compatriots' of fatty liver disease health becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.The average attack rate of (white collar personage, taxi driver, professional manager, individual proprietor, government official, high level intellectual etc.) fatty liver is 25% in some professional population; The sickness rate of fatty liver is 50% among obese people and the type ii diabetes patient; Be addicted to drink and the sickness rate of alcoholic fatty liver is 58%; The sickness rate of fatty liver is about 60% in often insomnia, tired, the sub-health population of not thinking ordinary food and drink, gastrointestinal dysfunction.Fatty liver crowd's age also constantly descends in recent years, and the mean age has only 40 years old, and the patient about 30 years old is also more and more.Male's fatty liver is obviously more than the women below 45 years old.Fatty liver is a kind of common clinical picture, but not a kind of independently disease.The lighter is asymptomatic in its clinical manifestation, weight person's state of an illness ferociousness.Generally speaking, fatty liver belongs to the reversibility disease, and early diagnosis and in time slight fatty liver have only tired sense, and most Patients with Fatty Liver is more fat, so the slight subjective symptoms of more difficult discovery.In severe fatty liver the performance of similar chronic hepatitis is arranged, inappetence, lassitude and weak can be arranged, feel sick, vomit, lose weight, hepatic region or upper right abdomen dull pain etc.Treatment often can recover normal.
Fatty liver can cause five kinds of commonly encountered diseases: 1. liver cirrhosis and hepatocarcinoma.Fatty liver can not get treatment for a long time can cause the hepatocyte ischemic necrosis, thereby brings out multiple pernicious hepatopathys such as hepatic fibrosis and liver cirrhosis.The probability of the concurrent liver cirrhosis of Patients with Fatty Liver, hepatocarcinoma is 150 times of normal person.2. digestive system disease.3. atherosclerosis and cardiovascular and cerebrovascular disease.4. influence sexual function.5. affect one's power of vision.
So far, Western medicine does not still have lipotropic active drug, is mainly fat-reducing medicament.The toxic and side effects of Western medicine lipid-regulation medicine only reaches edge level or the less crowd of coronary heart disease risk for blood fat, does not advocate the use lipid-regulation medicine, and is best with the treatment of Chinese medicine long-time conditioning.Best with Radix Polygoni Multiflori Preparata and Fructus Crataegi in the Chinese medicine, these two kinds of medicines energy blood fat reducing prevent that cholesterol is at intrahepatic deposition.Western medicine is often selected protection hepatocyte, degrease medicine and antioxidant etc. for use; as vitamin B, C, E, lecithin, ursodesoxycholic acid, silymarin, inosine, coenzyme A, reduced glutathion, taurine, carnitine Orotate, glucuronolatone, and some fat-reducing medicament (for example: the liver purport is clear) or the like.Though said medicine is a lot, still needs further to verify its curative effect and safety mostly.
Summary of the invention
The object of the invention provides a kind of Chinese medicine preparation for the treatment of fatty liver, treats requirement safely and efficiently to satisfy fatty liver.
The Chinese medicine preparation of treatment fatty liver, it adopts the raw material of Chinese medicine of following weight ratio to make: Rhizoma Polygonati 10-30, Fructus Lycii 10-15, Fructus Canarii 12-30, Radix Scrophulariae 6-15, Fructus Amomi 3-6, Flos puerariae lobatae 12-20, Fructus Amomi Rotundus 3-6, Rhizoma Alismatis 10-15, Rhizoma Atractylodis Macrocephalae 3-12, Poria 10-30, Polyporus 10-15.
The present invention preferentially recommends to adopt the raw material of Chinese medicine of following weight ratio to make: Rhizoma Polygonati 20, Fructus Lycii 15, Fructus Canarii 15, Radix Scrophulariae 13, Fructus Amomi 6, Flos puerariae lobatae 15, Fructus Amomi Rotundus 6, Rhizoma Alismatis 13, the Rhizoma Atractylodis Macrocephalae 12, Poria 20, Polyporus 13.
Each prescription effect of the present invention is:
Rhizoma Polygonati-nourishing YIN and moistening the lung, invigorating the spleen and replenishing QI; Fructus Lycii-profit invigorating the liver and kidney, nourishing the liver to improve visual acuity; Fructus Canarii-removing heat from the lung and relieving sorethroat, toxin expelling; Radix Scrophulariae-nourshing Yin and drynsessmoistening prescription, the pathogenic fire reducing detoxifcation; Fructus Amomi-promoting the circulation of QI to relieve pain, the kidney warming cough-relieving, warming spleen and stopping diarrha; Flos puerariae lobatae-row's flesh is brought down a fever, promoting the production of body fluid to quench thirst, treating measles, yang invigorating antidiarrheal; Fructus Amomi Rotundus-promoting the circulation of QI to relieve pain, removing dampness expectorant, stomach warming cough-relieving; Rhizoma Alismatis-promoting diuresis to eliminate damp pathogen expels the heat-evil; The spleen invigorating invigorating middle warmer, mind tranquilizing and the heart calming; The Rhizoma Atractylodis Macrocephalae-invigorating the spleen and replenishing QI, dampness diuretic, strengthening superficial resistance to stop perspiration; Poria-promoting diuresis to eliminate damp pathogen, spleen invigorating invigorating middle warmer, mind tranquilizing and the heart calming; Zhu -promoting diuresis to eliminate damp pathogen.
The curative effect report of preparation for treating non-alcoholic fatty liver disease of the present invention.Adopt the method for parallel control at random, 108 routine Patients with Fatty Liver are divided into treatment group and matched group.78 routine oral preparations of the present invention are organized in treatment, and matched group 30 routine oral fluvastatins, glucuronolatone sheet treated for 8 weeks altogether.Observe treatment front and back tcm symptom, sign, syndrome integration and liver B ultrasonic ultrasonogram and change situation, estimate clinical efficacy.The result treats back treatment group total effective rate and obviously is better than matched group, and difference has statistical significance (P＜0.05).Proof the present invention treats fatty liver clinical efficacy preferably.
The specific embodiment
Prescription 1:
Rhizoma Polygonati 20, Fructus Lycii 15, Fructus Canarii 15, Radix Scrophulariae 13, Fructus Amomi 6, Flos puerariae lobatae 15, Fructus Amomi Rotundus 6, Rhizoma Alismatis 13, the Rhizoma Atractylodis Macrocephalae 12, Poria 20, Polyporus 13, each component are in the gram weight, and the pulverizing of cleaning back is made powder and got final product.
Prescription 2:
Rhizoma Polygonati 10, Fructus Lycii 15, Fructus Canarii 12, Radix Scrophulariae 15, Fructus Amomi 3, Flos puerariae lobatae 20, Fructus Amomi Rotundus 3, Rhizoma Alismatis 15, the Rhizoma Atractylodis Macrocephalae 3, Poria 30, Polyporus 10.Each component in gram is heavily cleaned back water extraction extractum and is made electuary.
Prescription 3:
Rhizoma Polygonati 30, Fructus Lycii 10, Fructus Canarii 30, Radix Scrophulariae 6, Fructus Amomi 6, Flos puerariae lobatae 12, Fructus Amomi Rotundus 6, Rhizoma Alismatis 10, the Rhizoma Atractylodis Macrocephalae 12, Poria 10, Polyporus 15.Each component in gram is heavily cleaned the back water extract and is made capsule.
The present invention preferentially recommends to adopt the raw material of Chinese medicine of following weight ratio to make:
From year October in October, 2006-2009, the inventor adopts preparation for treating non-alcoholic fatty liver disease 78 examples of the present invention, and is evident in efficacy, and with doctor trained in Western medicine group controlled observation, existing the result is reported as follows.
1 data and method
1.1 standard compliant patient's 108 examples of physical data picked at random out-patient department health check-up.78 examples are organized in treatment, wherein male 42 examples, women 36 examples, 26～69 years old age, medical history 40 days～20 years.Matched group 30 examples, wherein male 18 examples, women 12 examples; 24～71 years old age; Medical history 40 days～25 years.Treat physical data such as preceding sex, age, the course of disease relatively, the equal not statistically significant of difference for two groups.
1.2 include the non-alcoholic fatty liver disease diagnostic criteria that standard reference Chinese Medical Association hepatology branch fatty liver and alcoholic liver disease group are formulated in; All possess that any one can be included in following the 1st～5 and the 6th or the 7th.(1) no history of drinking history or drink amount to the amount of alcohol male weekly＜140g, the women weekly＜70g; (2) viral hepatitis, medicine fatty liver, total parenteral nutrition, hepatolenticular degeneration etc. can cause the specified disease of fatty liver except; (3) except that the primary disease clinical manifestation, nonspecific symptom and signs such as weak, dyspepsia, dull pain in liver, hepatosplenomegaly can be arranged; (4) can have overweight and (or) metabolism syndrome related components such as internal organs obesity, fasting glucose increase, blood fat disorder, hypertension; (5) serum transaminase and gamma glutamyl transpeptidase level can have gently, moderate increases, and increase based on alanine aminotransferase (ALT) usually; (6) the liver Radiologic imaging meets the imaging diagnosis standard of diffusivity fatty liver.
1.3 exclusion standard is because the hyperlipidemia patient that medicine (as phenothiazines, adrenocortical hormone and some contraceptive etc.) causes; Just heparin, thyroxine and other patients who influences metabolic medicine patient and use other blood fat reducing methods in nearly two weeks; Be associated with serious primary disease such as cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic system and psychotic; Trimester of pregnancy and women breast-feeding their children.
1.4 Therapeutic Method treatment group patient takes the preparation that the present invention's (dosage form is selected for use according to patient's situation) is equivalent to crude drug 6-9 gram at every turn, every day three times is with taking after the eliminating cold for resuscitation cooked rice reboiled in water or soup.Inactive any fat-reducing medicament is kept on a diet in right amount during the treatment, does aerobatic exercise more, detects blood fat and liver B ultrasonic after 8 weeks of the courses of treatment.Matched group: oral fat-reducing medicament lescol see fluvastatin (fluvastatin sodium capsule, Novartis Pharma AG, lot number x0193), 1 (40mg) of clothes before sleeping every night serve on and finishes back check blood fat 8 weeks.
2 therapeutic outcomes
2.1 " the clinical research guideline of new Chinese medicine treatment hyperlipidemia " criterion that criterion of therapeutical effect is issued with reference to health ministry.Traditional Chinese medical science curative effect determinate standard:
Recovery from illness: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=95%.
Produce effects: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=70%.
Effectively: clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=30%.
Invalid: clinical symptoms, sign do not have obvious improvement or increase the weight of, and the syndrome integration reduces less than 30%.
Fatty liver evaluation press the B ultrasonic ultrasonogram divide gently, in, severe.The lighter: liver section first half echo increases slightly slightly, strengthens, and the latter half of echo of liver section is lowered slightly, goes out liver face light belt and exists; Moderate: liver section first half echo is thick, and the latter half of echo of liver section is lowered and strong, goes out liver face light belt raising far field and strengthens and can occur; Severe: liver section first half echo obviously increases slightly, strengthens, and the latter half of echo of liver section disappears, and goes out liver face light belt and does not show.The normal recovery from illness that is is recovered in the treatment back, and progressive 1～2 grade of person is for alleviating, and the no change or the person of increasing the weight of are invalid.
2.2 the result changes relatively before and after detecting the index treatment: treatment back serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, ALT, Aspartic Acid aminotransferase (AST) value all have obvious decline before the treatment, and the HDL-C value has obvious rising (P＜0.05).78 routine patient's liver B ultrasonic and normal 41 examples of biochemical recovery thereof are organized in treatment, alleviate 28 examples, invalid 9 examples, total effective rate 88.5%.Normal 8 examples alleviate 15 examples in matched group 30 examples, invalid 7 examples, total effective rate 76.67%.Two groups of comparing differences have statistical significance (P＜0.05).
3 discuss
The traditional Chinese medical science belongs to the hyperlipemia fatty liver that expectorant is turbid, the phlegm-damp scope.From the function of traditional Chinese medical science the five internal organs, with the closest internal organs of human body lipid metabolism no more than spleen, The spleen has the function to transport and transform nutrients, comprises precise and tiny and two aspects of transmitting and distributing the fluids of transporting and transforming nutrients from foodstuff.A large amount of experimental results show, the multiple receptor of spleen and human body, enzyme in close relations, and some receptor, azymia cause the principal element of hyperlipemia just, so that hyperlipidemia comes from is insufficiency of the spleen, insufficiency of the spleen expectorant is turbid to be the key of primary disease.Poria, the Rhizoma Atractylodis Macrocephalae, Rhizoma Alismatis invigorating spleen to remove dampness in the side, the source that expectorant is not had grow; The Fructus Amomi promoting the circulation of QI to relieve pain, the kidney warming cough-relieving, warming spleen and stopping diarrha, Rhizoma Polygonati nourishing YIN and moistening the lung, invigorating the spleen and replenishing QI.The present invention adopts soothing liver and strengthening spleen, change fat to treat by turbid Chinese medicinal formulae, has reached beyond thought effect.
Claims (2)
1. the Chinese medicine preparation of treatment fatty liver is characterized in that adopting the raw material of Chinese medicine of following weight ratio to make: Rhizoma Polygonati 10-30, Fructus Lycii 10-15, Fructus Canarii 12-30, Radix Scrophulariae 6-15, Fructus Amomi 3-6, Flos puerariae lobatae 12-20, Fructus Amomi Rotundus 3-6, Rhizoma Alismatis 10-15, Rhizoma Atractylodis Macrocephalae 3-12, Poria 10-30, Polyporus 10-15.
2. the Chinese medicine preparation of treatment fatty liver according to claim 1 is characterized in that adopting the raw material of Chinese medicine of following weight ratio to make: Rhizoma Polygonati 20, Fructus Lycii 15, Fructus Canarii 15, Radix Scrophulariae 13, Fructus Amomi 6, Flos puerariae lobatae 15, Fructus Amomi Rotundus 6, Rhizoma Alismatis 13, the Rhizoma Atractylodis Macrocephalae 12, Poria 20, Polyporus 13.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105872179A CN102008678B (en) | 2010-12-14 | 2010-12-14 | Chinese medicinal preparation for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105872179A CN102008678B (en) | 2010-12-14 | 2010-12-14 | Chinese medicinal preparation for treating fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102008678A true CN102008678A (en) | 2011-04-13 |
| CN102008678B CN102008678B (en) | 2012-05-30 |
Family
ID=43839140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105872179A Expired - Fee Related CN102008678B (en) | 2010-12-14 | 2010-12-14 | Chinese medicinal preparation for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008678B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486710A (en) * | 2002-12-31 | 2004-04-07 | 张立中 | Chinese medicine for health care and treating fatty liver |
| CN101574476A (en) * | 2009-05-26 | 2009-11-11 | 徐琳 | Medicinal material composition used for lowering lipid and protecting liver auxiliarily |
-
2010
- 2010-12-14 CN CN2010105872179A patent/CN102008678B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486710A (en) * | 2002-12-31 | 2004-04-07 | 张立中 | Chinese medicine for health care and treating fatty liver |
| CN101574476A (en) * | 2009-05-26 | 2009-11-11 | 徐琳 | Medicinal material composition used for lowering lipid and protecting liver auxiliarily |
Non-Patent Citations (2)
| Title |
|---|
| 《陕西中医》 19991231 曹晓菊等 脂肪肝中医药治疗研究进展 第20卷, 第09期 2 * |
| 《陕西中医》 20080105 赵琦 祛脂愈肝汤加减治疗脂肪肝32例 第29卷, 第01期 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008678B (en) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536638B (en) | It is a kind of to treat medicine of gastrointestinal dysfunction and preparation method thereof | |
| CN102028900B (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| CN102920975B (en) | Traditional Chinese medicine for treating gastropathy and preparation method thereof | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN103027138B (en) | Tea for enlivening spleens and production method of tea | |
| CN103566346B (en) | A kind of medicine and preparation method for the treatment of person in middle and old age's abdominal distention | |
| CN102961525A (en) | Medicine composition for losing weight and reducing blood lipid in auxiliary manner and oral liquid preparation method thereof | |
| CN101953936B (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN101721667A (en) | Traditional Chinese medicine for treating indigestion | |
| CN101199817B (en) | Liver-protecting fat-dropping tea | |
| CN103005264B (en) | Chitosan oligosaccharide-containing healthcare food and preparation method thereof | |
| CN103989820B (en) | Medicament for treating hyperlipidemia | |
| CN107927781B (en) | Traditional Chinese medicine weight-losing meal replacement | |
| CN102626440B (en) | Traditional Chinese medicine composition for protecting liver and regulating blood fat | |
| CN102008678B (en) | Chinese medicinal preparation for treating fatty liver | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN106474413A (en) | A kind of Orally administered composition for treating child's weakness of the spleen and stomach, eating accumulation, anorexia | |
| CN104721414A (en) | Gynostemma pentaphylla lipid-lowering tea | |
| CN109395045A (en) | A kind of clearing away heat and eliminating dampeness tune sugar-pill and preparation method thereof for treating diabetes B MIDDLE ENERGIZER DAMPNESS-HEAT | |
| CN106266334A (en) | A kind of Chinese medicine composition treating fat concurrent hyperlipemia and acupuncture and drugs application | |
| CN103463578A (en) | Medicament for treating cholelithiasis, cholecystitis and hyperbilirubinemia | |
| CN103784924B (en) | Chinese medicine composition of a kind of antidiarrheal and preparation method thereof | |
| CN101926934B (en) | Medicine with protective function on gastric mucosa and liver injury and preparation method thereof | |
| CN100502927C (en) | Medication of three gen-seng and astragalus root and its preparation method | |
| CN105560696A (en) | Drug for treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20121214 |